SELLAS Life Sciences Group, Inc.
Late-stage biopharma developing novel immunotherapies for a broad range of cancers.
SLS | US
Overview
Corporate Details
- ISIN(s):
- US81642T2096 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 7 TIMES SQUARE, 10036 NEW YORK
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel immunotherapeutics for a broad range of cancer indications. The company's core activity is advancing its pipeline of cancer therapies designed to target and activate the patient's immune system against various tumors. Its lead product candidate, galinpepimut-S (GPS), is being developed for multiple hematologic malignancies and solid tumors, including acute myeloid leukemia (AML) and mesothelioma.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all SELLAS Life Sciences Group, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for SELLAS Life Sciences Group, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for SELLAS Life Sciences Group, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
%20LTD/other/Cuprina_Holdings_Cayman_LTD-logo.png){kind=logo}